JAMES J. BOCHNOWSKI - 11 Dec 2025 Form 4 Insider Report for Jaguar Health, Inc. (JAGX)

Role: Director
Signature: /s/ James J. Bochnowski
Issuer symbol: JAGX
Transactions as of: 11 Dec 2025
Transactions value $: $0
Form type: 4
Filing time: 15 Dec 2025, 17:57:47 UTC
Previous filing: 26 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
BOCHNOWSKI JAMES J	Director	C/O JAGUAR HEALTH, INC., 200 PINE ST., STE 400, SAN FRANCISCO	/s/ James J. Bochnowski	15 Dec 2025	0001255743

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	JAGX	Common Stock	Award	$0	+6.36K	+12236.54%	$0.00	6.42K	11 Dec 2025	Direct	F1, F2, F3, F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JAGX	Stock Option (right to buy)	Award	$0	+6.36K		$0.00	6.36K	11 Dec 2025	Common Stock	6.36K	$1.44	Direct	F1, F2, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Granted pursuant to the issuer's 2014 Stock Incentive Plan.
F2	The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.
F3	Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice.
F4	On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "2024 Reverse Stock Split"). Upon effectiveness of the 2024 Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock.
F5	On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "2025 Reverse Stock Split"). Upon effectiveness of the 2025 Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock.
F6	The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the reporting person continues to serve on the board of directors of the issuer.